Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefts to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Identifying predictive non-invasive biomarkers of immunotherapy response is crucial to avoid premature treatment interruptions or ineffective prolongation. Our aim was to develop a non-invasive biomarker for predicting immunotherapy clinical durable benefit, based on the integration of radiomics and clinical data monitored through early anti-PD-1/PD-L1 monoclonal antibodies treatment in patients with advanced non-small cell lung cancer (NSCLC)… Integrating multidimensional and longitudinal data improved clinical durable benefit prediction to immunotherapy treatment of advanced non-small cell lung cancer patients. The selection of effective treatment and the appropriate evaluation of clinical benefit are important for better managing cancer patients with prolonged survival and preserving quality of life.

immunotherapy; lung cancer; clinical durable benefit; deep-radiomics; clinical data; longitudinal analysis; treatment monitoring

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefts to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients Articles